Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of cenobamate adjunctive therapy in primary generalized tonic-clonic seizures
2018-002981-37Phase 3Active
- Sponsor
- SK Life Science, Inc.
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cenobamate in generalized tonic-clonic seizure (GTCS) and epilepsy, sponsored by SK Life Science, Inc. Primary endpoints: Incidence of adverse events, Incidence of serious adverse events and 4 more. Started Jul 2019; status: active.
02
Drugs
cenobamate
03
Conditions
generalized tonic-clonic seizure (GTCS)epilepsy
Beyond the preview
Go deeper on 2018-002981-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002981-37.